Tobramycin Cisplatin

Clinically important, potentially hazardous interactions with altretamine, amikacin, aminoglycosides, antineoplastics, bleomycin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, corticosteroids, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, estramustine, etoposide, fludarabine, fluorouracil, gemcitabine, gentamicin, hydroxyurea, idarubicin, ifosfamide, indomethacin, kanamycin, levamisole, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, neomycin, pentostatin, plicamycin, procarbazine, streptomycin, streptozocin, thioguanine, thiotepa, tobramycin, tretinoin, uracil, vinblastine, vincristine, vinorelbine... 

Clinically important, potentially hazardous interactions with ACE inhibitors, amikacin, aminoglycosides, aminophylline, anti-diabetics, antihypertensives, cephalosporinss, cisplatin, gentamicin, indomethacin, kanamycin, neomycin, probenecid, salicylates, streptomycin, tobramycin... 

Bregman CL, Williams PD. Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin. Cancer Chemother Pharmacol 1986 18(2) 117-123. 

The renal toxicity of cisplatin is potentiated by aminoglycoside antibacterials such as gentamicin and tobramycin. Extra care is required in patients treated with cisplatin requiring these antibacterials. In one retrospective analysis in patients taking cisplatin, hearing loss was not associated with the concurrent use of ototoxic drugs, including tobramycin. 

There is also evidence from a study in children to show that previous treatment with cisplatin is a risk factor for the delayed elimination of aminoglycosides (gentamicin, amikacin, tobramycin). ... 

---